– Welsh Government spokesperson
The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
The Cystic Fibrosis Trust has written a letter to the Welsh Government, calling on it to speed up decision-making on a 'life-changing' drug called Kalydeco, which is available to patients in England and will soon be to those in Scotland.